Eastman Chemical Co.

DUBLIN--( BUSINESS WIRE )--The "Biopharmaceutical Excipients Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Biopharmaceutical Excipients Market was valued at USD 2.43 billion in 2023, and is expected to reach USD 3.79 billion by 2029, rising at a CAGR of 7.69% The global biopharmaceutical excipients market report contains exclusive data on 36 vendors. The market is characterized by diverse vendors, from emerging mid-sized companies to well-established players, contributing to its revenue. Leading companies are employing various strategies to increase their market share and presence. These include launching new products, securing approvals, engaging in marketing and promotional activities, investing heavily in R&D, and strengthening their distribution networks. Major players such as Merck KGaA, BASF SE, Avantor, Evonik Industries, Roquette Freres, Associated British Foods, and others are also focusing on strategic licensing, acquisitions, and collaboration agreements with emerging companies to quickly enter the biopharmaceutical excipients market and access commercially available products. Expanding into existing and new markets to meet the needs of a growing customer base, broadening product portfolios, and enhancing production capabilities are key strategies to attract end-users. Additionally, companies are introducing advanced and novel excipient solutions to support pharmaceutical drug development, ensuring robust distribution chains to meet market demand. APAC shows significant growth, with the fastest-growing region in the global biopharmaceutical excipients market. The APAC region is poised for significant growth, driven by several key factors. The region's expanding pharmaceutical industry, advancements in functional excipients, and the rising use of orphan drugs underscore robust growth prospects. The emergence of multifunctional excipients and the shift of pharmaceutical manufacturing to emerging markets further enhance these prospects. Additionally, the burgeoning biosimilar industry in APAC presents new opportunities for excipients used in biopharmaceutical formulations. The region is witnessing an increasing target patient population, particularly those affected by cancer, which remains the second-highest cause of death globally. MARKET TRENDS & DRIVERS Demand for Novel Excipients in Advancing Biopharmaceutical Development Developing new and improved biopharmaceutical drugs relies on novel excipients essential for advanced product formulations. Unlike conventional excipients, these novel substances have not been used in FDA-approved drug products and lack established food use. Advocates highlight their public health benefits, including enhanced drug delivery and their utility in abuse-deterrent opioid formulations. Recognition by the FDA as novel excipients would assure drug developers of their safety, reducing concerns during application review. While many approved drug excipients are listed in the FDA's Inactive Ingredient Database (IID) and have been used for decades, novel excipients are typically not included in the IID. They may be intended for new administration routes, higher dosages, or modifications like particle engineering. In a significant step towards modernizing drug formulation, the FDA has initiated a program to test the safety and suitability of novel inactive ingredients for new drugs and biologics. This initiative encourages using novel excipients in clinical trials, providing excipient suppliers with a faster route to market and promoting innovative therapies. Increasing Demand for Excipients in Vaccine and Regenerative Medicine Formulations Excipients play a critical role in stabilizing vaccines and developing regenerative medicines, ensuring safety, stability, and efficacy. Vaccines, inherently unstable and prone to degradation, require various excipients like diluents, preservatives, stabilizers, adjuvants, and buffering agents. For instance, preservatives such as formaldehyde prevent contamination, while stabilizers like sucrose and gelatin maintain potency during storage and transport. Aluminum salts are used as adjuvants, enhancing immune response, and buffering agents like sodium chloride maintain pH balance. In regenerative medicine, the demand for novel excipients is rising, driven by the growth in cell and gene therapies to treat rare diseases. These therapies utilize excipients such as buffers, salts, polymers, and proteins to stabilize formulations and ensure physiological osmolality. The investment in cell and gene therapy has surged, necessitating innovative excipients to support the development of advanced therapeutic solutions. Strategic Outsourcing in Biopharmaceutical Excipient Manufacturing Pharmaceutical companies are increasingly outsourcing the manufacturing of biopharmaceutical excipients due to several key factors. Rapid advancements in biopharmaceutical R&D have created a need for specialized excipients that enhance drug efficacy, stability, and delivery, requiring complex and costly manufacturing processes. Outsourcing allows pharmaceutical firms to focus on core activities like drug discovery, clinical trials, and regulatory affairs, leveraging the expertise of specialized manufacturers to streamline operations and accelerate market entry for new therapies. Outsourcing also provides flexibility and scalability, enabling companies to adjust capacity and maintain compliance with evolving regulatory standards, ensuring a reliable supply chain. Additionally, it offers cost-effectiveness by reducing the capital expenditures for in-house manufacturing facilities and allowing more efficient resource allocation while maintaining high-quality standards. The need for innovation, operational efficiency, regulatory compliance, and cost savings drives the trend toward outsourcing. INDUSTRY RESTRAINTS Supply Chain and Integrity Issues with Biopharmaceutical Excipients The integrity and reliability of the biopharmaceutical excipient supply chain are crucial for the quality and efficacy of biopharmaceutical products. This complex global supply chain, involving multiple suppliers and distributors, poses significant challenges. Though pharmacologically inert, excipients require strict management to prevent adulteration and ensure patient safety. The rise of novel excipients and delivery systems amplifies the need for robust quality control, certification, and supply chain management. The extended supply chains and increased importation introduce risks of counterfeit or substandard excipients, potentially causing production delays and adverse effects. Ensuring compliance with Good Manufacturing Practices (GMP) and regulatory standards is essential. Historical incidents, such as the 2012 contamination with industrial-grade gelatin, highlight the importance of strict controls. Regulatory bodies like the FDA and China's SFDA have enforced stricter regulations on high-risk excipients. To maintain market growth, pharmaceutical manufacturers must prioritize high-quality excipients, adhering to stringent regulatory requirements despite the complexities of the supply chain. KEY QUESTIONS ANSWERED: How big is the global biopharmaceutical excipients market? What is the growth rate of the global biopharmaceutical excipients market? What are the key trends in the global biopharmaceutical excipients market? Which region shows the highest growth in the global biopharmaceutical excipients market? Who are the major players in the global biopharmaceutical excipients market? Key Attributes: Report Attribute Details No. of Pages 163 Forecast Period 2023 - 2029 Estimated Market Value (USD) in 2023 $2.43 Billion Forecasted Market Value (USD) by 2029 $3.79 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Key Vendors Merck KGaA BASF SE Avantor Evonik Industries AG Roquette Freres Associated British Foods plc Other Prominent Vendors Actylis Advancion Apothecon Pharmaceuticals Ashland BioSpectra BOC Sciences CG Group Clariant Colorcon DFE Pharma Dow Eastman Chemical Company IMCD Innophos InVitria ABITEC CordenPharma Croda International plc JRS Pharma Kirsch Pharma MEGGLE Novo Nordisk Pfanstiehl Shin-Etsu Chemical Sigachi Industries Spectrum Chemical Stepan Company Tereos The Lubrizol Corporation WACKER CHEMI By Excipient Bulking Agents Solubilizers & Surfactants Buffering & Tonicity Agents Others By Biologics Monoclonal Antibodies Vaccines Others By Scale of Operation Commercial Research By Origin Organic Excipients Inorganic Excipients By End-User Pharma & Biotech Companies CMOs & CDMOs Academic & Research Institutes By Geography North America The U.S. Canada Europe Germany The U.K. France Italy Spain APAC Japan China India Australia South Korea Latin America Brazil Mexico Argentina Middle East & Africa Turkey South Africa Saudi Arabia For more information about this report visit https://www.researchandmarkets.com/r/7oy3j7 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

HOUSTON--( BUSINESS WIRE )--Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s unique dendritic cell vaccine (DCV) for pancreatic ductal adenocarcinoma. In addition, the company has named to its Scientific Advisory Board, Daniel D. Von Hoff, M.D., Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, AZ, and City of Hope, and an experienced investigator against pancreatic cancer. “This second FDA Fast Track designation of our autologous dendritic cell vaccines for pancreatic cancer is another acknowledgement of the incredible potential of this innovative immunotherapy for treating the most deadly cancers,” said Mike Wicks, Diakonos CEO. “We are thrilled to have Dr. Von Hoff join us as an advisor as we pursue clinical development of our vaccine in this deadly disease,” Mr. Wicks added. “The first designation was for our lead vaccine for glioblastoma multiforme (GBM) which successfully completed dosing for the Phase 1 trial and has significantly improved 12 month survival in those patients to well over what would be expected with the standard of care.” ( See the press release ) Dr. Von Hoff is an internationally recognized physician and scientist whose research has contributed to the development of many anticancer agents that are routinely used in clinical practice. His research at TGEN focuses on development of therapies for patients with advanced pancreatic cancer. He also was a founder of ILEX Oncology which was acquired by Genzyme. In addition to his work with TGEN, Dr. Von Hoff holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute, and is Professor of Medicine at the Mayo Clinic, Scottsdale, AZ. “Diakonos's unique dendritic cell vaccine has shown encouraging results in treating glioblastoma, a terrible disease with few effective treatments. Pancreatic cancer patients also need additional treatment options,” said Dr. Von Hoff. “I look forward to working with Diakonos to help develop effective treatments for patients with pancreatic cancer with the same targeted technology.” About FDA Fast Track: FDA Fast Track designation is intended to speed development and review of drugs that show early clinical promise in treating severe or life-threatening conditions. Pancreatic ductal adenocarcinoma is the most common pancreatic cancer. It is the third leading cause of cancer deaths in the U.S. and the number of cases is growing. According to the National Institutes of Health, the average five-year survival rate is less than 13%, and in 2024 an estimated 51,750 people will die and 66,440 will be newly diagnosed. About Diakonos’ DCV Technology: The company’s DCVs are made with a patient’s dendritic cells and a sample of their tumor. These highly differentiated double-loaded dendritic cell vaccines activate robust cytotoxic T H 1 cell signaling pathways that initiate a natural immune response to target and eliminate cancer cells. This is achieved without any genetic modification of the patient’s immune cells, which greatly simplifies the manufacturing process and significantly reduces costs when compared to leading cell therapy approaches. About Diakonos Oncology Corp. Based in Houston, TX, Diakonos Oncology is a clinical-stage biotechnology company dedicated to revolutionizing cancer immunotherapy and focusing on difficult-to-treat indications, including glioblastoma and PDAC. A variant of the DOC1021 treatment platform are also in early-stage clinical testing in angiosarcoma (AS). For more information visit: www.diakonosoncology.com .

DUBLIN--( BUSINESS WIRE )--The "Medical Plastics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Medical Plastics Market to Reach $50.5 Billion by 2030 The global market for Medical Plastics estimated at US$31 Billion in the year 2022, is projected to reach a revised size of US$50.5 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2022-2030. Engineering Plastics, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the High Performance Plastics (hpp) segment is estimated at 7.6% CAGR for the next 8-year period. The U.S. Market is Estimated at $8.2 Billion, While China is Forecast to Grow at 7.8% CAGR The Medical Plastics market in the U.S. is estimated at US$8.2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$8.2 Billion by the year 2030 trailing a CAGR of 7.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 5.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.1 Billion by the year 2030. What`s New? Special discussions on the global economic climate and market sentiment Coverage on global competitiveness and key competitor percentage market shares Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and research platform Complimentary updates for one year Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes Key Attributes: Report Attribute Details No. of Pages 604 Forecast Period 2022 - 2030 Estimated Market Value (USD) in 2022 $31 Billion Forecasted Market Value (USD) by 2030 $50.5 Billion Compound Annual Growth Rate 6.3% Regions Covered Global MARKET OVERVIEW Plastics in Healthcare: Pioneering New Frontiers in Medical Device Evolution Trends Shaping the Medical Devices and Medical Plastics Industries Medical Plastics - A SWOT Analysis Global Economic Update COVID-19 Revives Interest in Plastics for Medical Industry Competitive Market Presence - Strong/Active/Niche/Trivial for 97 Players Worldwide in 2023 (E) Plastics Used in Medical Devices Types of Medical Plastics Recent Market Activity MARKET TRENDS & DRIVERS Bioplastics in the Medical Sector: A Sustainable Innovation Gaining Interest Growing Applications of Bioresorbable and Biodegradable Polymers Biodegradable Polymers in Nano Drugs: A Growing Market Rise in Importance of 3D Printing in Manufacturing of Medical Devices Multi-Jet Fusion Technology: Revolutionizing Medical 3D Printing PEEK Emerges as a Key Material for 3D Printing Medical Devices Micro-Moulding Medical Plastics, an Essential Manufacturing Technique for Implants and other Medical Devices Silicone Gains Increased Acceptance in Medical Applications Growing Prominence of Silicone in Surgical and Medical Device Bonding Drive Demand in Medical Applications Wearable Medical Devices: A Lucrative End-use Market for Medical Silicone Silicone Elastomers Gain Attractive Penetration in Medical & Healthcare Industry Growing Adoption of Medical Robots Creates Demand for High Strength Plastics Advancements in Medical Plastics and Production Capabilities Drive Innovative Applications Growing Demand for Point of care Diagnostics Drive Gains Plastics Aid Artificial Organs Revolutionize Medical Industry Engineered Resins Continue to Evolve PEEK Polymers Gain Importance in Orthopedic Implants Thermoplastic Elastomers Find Growing Use in Medical Industry Rising Popularity of TPEs for Medical Tubing Applications Antimicrobial Plastics for Medical Devices Gain Prominence Trends in Decorating Techniques Used in Medical Device Manufacture Disposables Widen Demand for Advanced Polymers Medical Device Packaging: A Pivotal Aspect of Modern Healthcare System Sterilization Techniques Play a Vital Role in Selection of Polymers for Medical Applications Sustainable Healing: Pioneering the Recycling Revolution in Medical Plastics Rise in Healthcare Expenditure to Drive Growth Demographic Trends Push the Market Ahead FOCUS ON SELECT PLAYERS (Total 97 Featured) BASF SE Lanxess AG Eastman Chemical Company Kuraray Co., Ltd. Exxon Mobil Corporation Covestro AG Chi Mei Corporation AdvanSource Biomaterials Corporation Invibio Ltd. Addiplast SA Engineered Polymers (India) Pvt., Ltd. Distrupol Ltd. Elix Polymers SLU Kraton Corporation GW Plastics, Inc. For more information about this report visit https://www.researchandmarkets.com/r/kq5v44 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.